AstraZeneca vs Disney: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: AstraZeneca and Disney side by side

1. 1913AstraZeneca

   Astra AB Founded in Södertälje, Sweden

   400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies.

2. 1923Disney

   Disney Brothers Cartoon Studio is founded

   Walt Disney and Roy O. Disney formed the studio after Walt arrived in California with the Alice Comedies.

3. 1928Disney

   Mickey Mouse debuts in Steamboat Willie

   Steamboat Willie introduced Mickey Mouse to a broad audience with synchronized sound. The short helped Disney turn a technical change in cinema into a character asset that could be repeated, licensed, and expanded.

4. 1937Disney

   Snow White and the Seven Dwarfs is released

   Snow White and the Seven Dwarfs proved that feature-length animation could work as a premium theatrical event. Its success gave the studio credibility and capital for more ambitious animated films.

5. 1955Disney

   Disneyland opens in Anaheim

   Disneyland moved the company beyond screens and into physical entertainment. The park created a second economic model built on admission, food, merchandise, hospitality, and repeat family visits.

6. 1993AstraZeneca

   Zeneca Group Spun Off from ICI

   Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales.

7. 1996Disney

   Capital Cities/ABC brings ESPN to Disney

   Disney stockholders approved the Capital Cities/ABC merger in 1996, bringing ABC and ESPN into the company. ESPN later became central to Disney's television economics and is now central to its cord-cutting risk.

8. 1999AstraZeneca

   Astra and Zeneca Merge to Form AstraZeneca

   The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC.

9. 2000AstraZeneca

   Nexium Launch Replaces Prilosec

   AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001.

10. 2005Disney

    Robert A. Iger becomes CEO

    Iger became CEO in 2005 after serving as Disney president and chief operating officer. His tenure reshaped the company through Pixar, Marvel, Lucasfilm, 21st Century Fox assets, international expansion, and direct-to-consumer streaming.

11. 2006AstraZeneca

    Acquisition of Cambridge Antibody Technology

    AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion.

12. 2006Disney

    Pixar Animation Studios is acquired

    The $7.4B Pixar deal ended a strained distribution relationship and brought creative leadership, computer-animation expertise, and a strong story process into Disney. It helped restore animation momentum and set the template for later franchise acquisitions.

13. 2007AstraZeneca

    Acquisition of MedImmune for $15.6 Billion

    AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.

14. 2009Disney

    Marvel Entertainment is acquired

    Disney agreed to acquire Marvel in a transaction valued at about $4B. The deal added more than 5,000 characters and expanded the company's reach in theatrical films, consumer products, streaming, and parks.

15. 2012AstraZeneca

    Pascal Soriot Appointed CEO

    Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment.

16. 2012Disney

    Lucasfilm joins Disney

    The Lucasfilm acquisition was valued at $4.05B and brought Star Wars, Indiana Jones, Industrial Light & Magic, and related production assets. It gave Disney a global franchise with theatrical, streaming, merchandise, games, and parks potential.

17. 2014AstraZeneca

    Pfizer Hostile Takeover Rejected

    AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential.

18. 2014AstraZeneca

    Acquisition of Almirall Respiratory Portfolio

    AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.

19. 2015AstraZeneca

    Tagrisso Approved for EGFR-Mutated Lung Cancer

    The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market.

20. 2017AstraZeneca

    Imfinzi Approved Based on PACIFIC Trial

    The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits.

21. 2019Disney

    Disney signs amended 21st Century Fox acquisition agreement

    The amended Fox agreement valued the equity consideration at about $71.3B and expanded Disney's content library, international assets, and Hulu position. It was a scale move made as Disney prepared for a streaming-centered media market.

22. 2019Disney

    Disney+ launches

    Disney+ launched in the United States, Canada, and the Netherlands with nearly 500 films and 7,500 television episodes. The service moved Disney closer to consumers and made streaming economics a core investor question.

23. 2020AstraZeneca

    COVID-19 Vaccine Development with Oxford University

    AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak.

24. 2020Disney

    Bob Chapek leads through pandemic disruption

    Chapek became CEO shortly before COVID-19 disrupted parks, cruises, theaters, and production. The period exposed Disney's dependence on physical attendance while accelerating demand for direct-to-consumer streaming.

25. 2021AstraZeneca

    Acquisition of Alexion Pharmaceuticals for $39 Billion

    AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston.

26. 2023AstraZeneca

    CinCor Pharma Acquired for up to $1.8 Billion

    AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension.

27. 2024AstraZeneca

    Total Revenue Reaches $54.073 Billion

    AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.

28. 2024AstraZeneca

    Fusion Pharmaceuticals and Gracell Acquisitions

    AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.

29. 2025AstraZeneca

    Total Revenue Reaches $58.739 Billion

    AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.

30. 2025AstraZeneca

    EsoBiotec Acquired for Up to $1 Billion

    AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.

31. 2025AstraZeneca

    $50 Billion US Manufacturing and R&D Commitment

    AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion.

32. 2025Disney

    $94.425B revenue and $12.404B net income

    FY2025 results showed the scale of Disney's current base across Entertainment, ESPN, and Experiences. The figures shift the analysis from simple revenue recovery to the quality of earnings, streaming profit, and park capital returns.

33. 2026AstraZeneca

    Ordinary Shares Begin Trading on the NYSE

    AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026.

34. 2026AstraZeneca

    Baxfendy Approved in the US for Hypertension

    The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled.

35. 2026AstraZeneca

    $15 Billion China Investment Through 2030

    AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue.

36. 2026Disney

    Josh D'Amaro becomes CEO

    Disney's board unanimously elected Josh D'Amaro CEO effective March 18, 2026, with Robert A. Iger moving to senior advisor and Dana Walden becoming President and Chief Creative Officer.

Acquisitions

Questions about AstraZeneca vs Disney